Literature DB >> 2970972

Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies.

C D Tsoukas1, J D Lambris.   

Abstract

The biologic effects of the third component of complement, C3, are mediated via receptors which specifically bind the enzymatic degradation products resulting from the cleavage of C3. One of the products, C3d, has been associated with binding to the second complement receptor CR2 (CD21). This receptor, which is identical to the receptor for Epstein-Barr virus (EBV), has been primarily found on cells of the B lineage, but not on mature T cells or other cells of erythroid or myeloid lineages. In the present investigation, we report the presence of CR2 on human thymocytes. Indirect immunofluorescence analysis employing monoclonal anti-CR2 antibodies revealed a range of thymocyte reactivity from 15% to 63% in thirteen experiments using cells of different donors. Reactivity was always greater with the monoclonal anti-CR2 (CD21) antibody HB-5 than with two other antibodies which recognize distinct epitopes on the CR2 molecule. Two-color immunofluorescence analysis indicated that the brightest of the HB-5-stained thymocytes also reacted with the monoclonal anti-CD1 antibody T6 (immature thymocyte marker) while some of the duller HB-5-staining cells reacted with the monoclonal anti-CD3 antibody Leu-4 (mature thymocyte marker). Immunoprecipitation of CR2 on thymocytes with antibody HB-5 and polyacrylamide gel electrophoretic analysis revealed a protein of 145 kDa molecular mass which is consistent with the size of CR2 found on B lymphocytes. These findings raise several questions regarding the biologic role of CR2-EBV receptor on cells of the T lineage.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2970972     DOI: 10.1002/eji.1830180823

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  23 in total

1.  B-cell antigens within normal and activated human T cells.

Authors:  G P Sandilands; M Perry; M Wootton; J Hair; I A More
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

2.  Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes.

Authors:  H Illges; M Braun; H H Peter; I Melchers
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

3.  Preferential localization of the Epstein-Barr virus (EBV) oncoprotein LMP-1 to nuclei in human T cells: implications for its role in the development of EBV genome-positive T-cell lymphomas.

Authors:  Jingwu Xu; Ali Ahmad; José Menezes
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 4.  Complement receptors and the shaping of the natural antibody repertoire.

Authors:  V Michael Holers
Journal:  Springer Semin Immunopathol       Date:  2004-12-22

Review 5.  Epstein-Barr virus tissue tropism: a major determinant of immunopathogenesis.

Authors:  L Hutt-Fletcher
Journal:  Springer Semin Immunopathol       Date:  1991

Review 6.  Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.

Authors:  Franklin R Toapanta; Ted M Ross
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 7.  Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2.

Authors:  Dong Liu; Jian-Ying Zhu; Zhong-Xiang Niu
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

8.  Origin and properties of soluble CD21 (CR2) in human blood.

Authors:  N R Ling; D L Hardie; G D Johnson; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

9.  Ablation of the cellular prion protein, PrPC, specifically on follicular dendritic cells has no effect on their maturation or function.

Authors:  Laura McCulloch; Karen L Brown; Neil A Mabbott
Journal:  Immunology       Date:  2013-03       Impact factor: 7.397

10.  Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia.

Authors:  N Ling; T Hansel; P Richardson; B Brown
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.